IPO Research Report -Yatharth Hospital and Trauma Care Services Limited
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Yatharth Hospital and Trauma Care Services Ltd.
Company Background
Yatharth Hospital and Trauma Care Services Limited (YHTCL) was incorporated on February 28, 2008. It is a multi-care hospital chain. It rank among the top 10 largestprivate hospitals in the National Capital Region of Delhi. Yatharth Hospital presently operates three super specialty hospitals situated in Delhi NCR, i.e., at Noida, Greater Noida, and Noida Extension, Uttar Pradesh. It offer healthcare services across numerous specialties and super specialties. A team of 609 doctors is engaged with the company.
Issue Details
Fresh Issue of Equity shares aggregating upto ?490 Cr and Offer for sale of 6,551,690 Equity Shares.
Issue Objectives
1. Repayment/ prepayment, in full or part, of certain borrowings availed by the Company.
2. Repayment/ prepayment, in full or part, of certain borrowings availed by the Subsidiaries, namely, AKS Medical & Research Centre Private Limited and Ramraja Multispeciality Hospital & Trauma Centre Private Limited.
3. Funding capital expenditure expenses of the Company for two hospitals, namely, Noida Hospital and Greater Noida Hospital.
4. Funding capital expenditure expenses of the Subsidiaries, AKS and Ramraja, for respective hospitals operated by them.
5. Funding inorganic growth initiatives through acquisitions and other strategic initiatives.
6. General corporate purposes.
IPO share allotment pattern
Outlook and Valuations
YHTCL is among the leading super specialty hospital in Delhi-NCR region with diverse specialty and payer mix. The company has advanced and high end medical equipment and technology. Further, we believe active collaborations with leading institutions and experts in different medical areas to improve their diagnostic and treatment capabilities and expansion in other geographical areas through inorganic growth to drive growth. At the upper price band of ?300/-, stock is priced at 29.73 of its FY23 EPS of 10.09. We recommend subscribing to the issue from a long term perspective.
To Read Complete Report & Disclaimer Click Here
Above views are of the author and not of the website kindly read disclaimer
